Mito Health Focuses on Prevention First Not Just Treatment

Six in ten adults suffer from a chronic illness in the US, yet much of the country’s healthcare system remains reactive which means they are designed to treat ailments after they arise rather than preventing them in the first place. Mito Health, founded by Teeming Chew, Joel Kek, Kenneth Lou, and Ryan Ware, a San Francisco-based AI-driven health company, is attempting to shift the focus toward proactive prevention. With a new $2.2 million infusion of seed funding, the company has now raised a total of $4 million.

Founded on the principle that early detection and personalized intervention can dramatically alter long-term health outcomes, Mito Health employs AI to analyze extensive health data. By integrating over 100 biomarkers, past medical records, and lifestyle factors, Mito Health creates tailored health optimization plans for its users. These insights guide individuals in adjusting their diet, exercise routines, supplement intake, and sleep patterns to improve their overall health and longevity.

_{Credits: Mito Health}

Since its launch in San Francisco last summer, Mito Health has expanded nationwide, forming key partnerships with leading laboratories such as LabCorp and BioReference. Its approach goes beyond simple biomarker analysis; it connects various health metrics, lifestyle factors, and personal medical history into a cohesive plan tailored to each user. The company’s platform has already demonstrated its effectiveness:

• 64% of users have identified and addressed elevated health risks.

• 36% have discovered vitamin or nutrient deficiencies.

• 4% have detected critical conditions requiring immediate medical intervention.

The latest funding round saw investments from Y Combinator, Capital X, XA Network, Balaji Srinivasan, Nir Eyal (bestselling author of Hooked), Kevin Aluwi (Co-founder of GoJek), Nas Daily, Alex Svanevik (CEO of Nansen), Prashanth Prakash (Partner at Accel), Dhruv Arora (Co-founder of Syfe), and existing investor Forge Ventures, among others. This network of backers signals a growing interest in AI-driven health solutions that go beyond traditional care models.

Alongside financial backing, Mito Health has expanded its scientific advisory board by welcoming renowned longevity researcher Professor Brian Kennedy. With over four decades of experience studying aging and the development of biological clocks such as LinAge, Kennedy brings significant expertise in longevity science to the company. His role will be pivotal in translating cutting-edge research into practical, personalized advice for Mito Health’s users.

_{Credits: Mito Health}

Mito Health’s growth across all 50 states has been fueled by its partnerships with diagnostic labs and health tech companies such as BodySpec (DEXA scans) and Prenuvo (preventative MRIs). These collaborations allow users to obtain deeper insights into their health beyond standard bloodwork. By integrating various forms of medical testing into a single platform, Mito Health aims to create the most comprehensive individual health profiles possible.

The company’s dashboard is designed to simplify complex biomarker data, ensuring that users can easily interpret their health metrics without requiring advanced medical knowledge. Customers can track 67 key biomarkers related to longevity and overall well-being, with AI-generated insights reviewed and refined by Mito Health’s medical team.

For example, while a high BMI might traditionally be flagged as a risk factor, Mito Health’s AI and medical team assess additional markers such as insulin sensitivity, creatinine levels, and training history to determine whether a person’s weight is due to muscle mass rather than excess fat. 

Mito Health emphasizes privacy and security in handling health data. The platform is fully PDPA compliant and employs encryption alongside strict access controls to ensure that only authorized personnel can view medical records. Users also have access to their original lab reports, making it easier to share verified results with external specialists if needed.

Beyond security, the platform offers a range of additional testing options, such as liquid biopsies through LUCENCE and expanded DEXA scans, allowing customers to gain an even more detailed understanding of their health.

One of Mito Health’s most promising developments is MitoMD, an AI-powered chatbot currently in beta testing. This feature is designed to assist users in interpreting their biomarker data, providing explanations in simple terms and answering personalized health questions. MitoMD aims to eliminate the confusion that often accompanies traditional lab reports by offering clear, actionable insights.

Mito Health’s $399 testing package is available nationwide, with results typically delivered within a week. The company’s focus extends beyond immediate health insights, incorporating risk horizon assessments that project potential health outcomes over the next 10, 20, and 30 years based on current lifestyle patterns. Regular check-ins and updates ensure that users stay on track with their health goals.

With the latest funding, Mito Health aims to enhance its AI capabilities further, refine its medical data integration, and expand its range of available tests. The company’s long-term ambition is to unify all health data into a single, user-friendly platform that empowers individuals to take full control of their well-being.

“As AI continues to advance, our vision of providing ‘an AI doctor in your pocket’ grows ever closer to reality,” said Mito Health Co-founder and CEO Kenneth Lou. “We believe that everyone deserves access to personalized, data-driven healthcare, and we are committed to making that a reality.”